- Home
- ANIX vs CLRB Comparison
ANIX vs CLRB Comparison
Compare ANIX & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- CLRB
- Stock Information
- Founded
- ANIX 1982
- CLRB 2002
- Country
- ANIX United States
- CLRB United States
- Employees
- ANIX N/A
- CLRB N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- CLRB Health Care
- Exchange
- ANIX Nasdaq
- CLRB Nasdaq
- Market Cap
- ANIX 108.9M
- CLRB 17.6M
- IPO Year
- ANIX 1987
- CLRB N/A
- Fundamental
- Price
- ANIX $3.17
- CLRB $4.89
- Analyst Decision
- ANIX Strong Buy
- CLRB Hold
- Analyst Count
- ANIX 3
- CLRB 2
- Target Price
- ANIX $9.00
- CLRB N/A
- AVG Volume (30 Days)
- ANIX 245.2K
- CLRB 209.7K
- Earning Date
- ANIX 09-05-2025
- CLRB 08-12-2025
- Dividend Yield
- ANIX N/A
- CLRB N/A
- EPS Growth
- ANIX N/A
- CLRB N/A
- EPS
- ANIX N/A
- CLRB N/A
- Revenue
- ANIX N/A
- CLRB N/A
- Revenue This Year
- ANIX N/A
- CLRB N/A
- Revenue Next Year
- ANIX N/A
- CLRB N/A
- P/E Ratio
- ANIX N/A
- CLRB N/A
- Revenue Growth
- ANIX N/A
- CLRB N/A
- 52 Week Low
- ANIX $2.07
- CLRB $4.36
- 52 Week High
- ANIX $4.20
- CLRB $94.50
- Technical
- Relative Strength Index (RSI)
- ANIX 49.47
- CLRB 33.92
- Support Level
- ANIX $3.18
- CLRB $4.62
- Resistance Level
- ANIX $3.39
- CLRB $5.17
- Average True Range (ATR)
- ANIX 0.18
- CLRB 1.09
- MACD
- ANIX -0.05
- CLRB -0.52
- Stochastic Oscillator
- ANIX 4.55
- CLRB 6.87
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.